Jennifer Childress - Concepedia

Author

Jennifer Childress

Baylor College of Medicine

Also Known As

Blakey, Carter, Jennifer Childress, Jennifer L Childress, Jennifer L. Childress

Publications

505

Citations

H-Index

Concepts

All Affiliations

Baylor College of Medicine The University of Texas MD Anderson Cancer Center Midwestern University Dana-Farber Cancer Institute University of California, San Francisco

About

Jennifer Childress is an author at Baylor College of Medicine specializing in medicine, cancer therapeutics, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	157
2	Pharmacology	2	2	55
3	Cell Biology	1	1	102
4	Cellular Physiology	1	1	102
5	Pathology	1	1	26

Jennifer Childress

Publications

469

Citations

H-Index

Page 1

	Year	Citations
Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease Alex E. Roher, Yu‐Min Kuo, Chera L. Esh, Molecular Medicine	2003	274
Lethal Giant Discs, a Novel C2-Domain Protein, Restricts Notch Activation during Endocytosis Jennifer Childress, Melih Acar, Chunyao Tao, Current Biology Developmental BiologyNovel C2-domain ProteinMedicineEndocytic PathwayIntracellular Trafficking	2006	102
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Erica Stringer-Reasor, Barbara O’Brien, Ariel R. Topletz‐Erickson, Journal of Clinical Oncology Breast OncologyPharmacotherapyPre-clinical PharmacologyOncologyMetronomic Therapy	2021	29
The Human Amyloid-β Precursor Protein770 Mutation V717F Generates Peptides Longer Than Amyloid-β-(40-42) and Flocculent Amyloid Aggregates Alex E. Roher, Tyler A. Kokjohn, Chera L. Esh, Journal of Biological Chemistry	2004	28
Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study Rashmi K. Murthy, Barbara O’Brien, Donald A. Berry, Cancer Research Breast OncologyPathologyAbstract Pd4-02Her2-positive Breast CancerOncology	2022	26
Best practices for problem lists in an EHR. Raeanna Bonetti, Joe Castelli, Jennifer Childress, PubMed	2008	10

Page 1